Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000166:cytology / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D000077143:Docetaxel; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D005079:Excipients / Q000737:chemistry / Q000494:pharmacology; D005990:Glycerol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D017239:Paclitaxel / Q000737:chemistry / Q000494:pharmacology*; D014677:Pharmaceutical Vehicles / Q000737:chemistry / Q000494:pharmacology; D011136:Polysorbates / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D043823:Taxoids / Q000737:chemistry / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D001798:Blood Proteins; D005079:Excipients; D014677:Pharmaceutical Vehicles; D011136:Polysorbates; D043823:Taxoids; D000077143:Docetaxel; C000515:cremophor EL; D017239:Paclitaxel; D005990:Glycerol